Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-06-10
2010-06-15
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S042000, C514S043000, C514S049000
Reexamination Certificate
active
07737128
ABSTRACT:
The invention is based on the discovery that specific dosages of pyrimidine compositions, such as uridine compositions, can be used to treat patients diagnosed with bipolar disorder.
REFERENCES:
patent: 4027017 (1977-05-01), Hata et al.
patent: 4048316 (1977-09-01), Penn
patent: 4115576 (1978-09-01), Penn
patent: 4386077 (1983-05-01), Borgo
patent: 4704361 (1987-11-01), Miccoli et al.
patent: 4764603 (1988-08-01), Zappia et al.
patent: 4999382 (1991-03-01), Wurtman et al.
patent: 5179126 (1993-01-01), Wurtman et al.
patent: 5278176 (1994-01-01), Lin
patent: 5409946 (1995-04-01), Garvey et al.
patent: 5472958 (1995-12-01), Gunn, Jr. et al.
patent: 5635486 (1997-06-01), Yamamoto et al.
patent: 5691320 (1997-11-01), von Borstel et al.
patent: 5691365 (1997-11-01), Crooks et al.
patent: 5888532 (1999-03-01), Pritsos et al.
patent: 5919789 (1999-07-01), Dyke et al.
patent: 5958896 (1999-09-01), Renshaw et al.
patent: 5977174 (1999-11-01), Bradley et al.
patent: 6103703 (2000-08-01), Renshaw et al.
patent: 6132724 (2000-10-01), Blum
patent: 6153653 (2000-11-01), Shashoua
patent: 6258794 (2001-07-01), Renshaw
patent: 6277855 (2001-08-01), Yerxa
patent: 6284268 (2001-09-01), Mishra et al.
patent: 6319953 (2001-11-01), Carlson et al.
patent: 6331568 (2001-12-01), Horrobin
patent: 6410522 (2002-06-01), Ruenberg
patent: 6503951 (2003-01-01), Pischel et al.
patent: 6541043 (2003-04-01), Lang
patent: 6608064 (2003-08-01), McLean et al.
patent: 6624195 (2003-09-01), Horrobin
patent: 6696495 (2004-02-01), Mueller
patent: 6727231 (2004-04-01), Page et al.
patent: 6852870 (2005-02-01), Stoll
patent: 6989376 (2006-01-01), Watkins et al.
patent: 7026301 (2006-04-01), Cardozo et al.
patent: 7053064 (2006-05-01), Lukas
patent: 2002/0019364 (2002-02-01), Renshaw
patent: 2002/0028787 (2002-03-01), Watkins et al.
patent: 2002/0182196 (2002-12-01), McCleary
patent: 2003/0100844 (2003-05-01), Miller et al.
patent: 2003/0114515 (2003-06-01), Wurtman et al.
patent: 2003/0220291 (2003-11-01), Renshaw
patent: 2003/0224435 (2003-12-01), Seiwert
patent: 2003/0232827 (2003-12-01), Meltzer et al.
patent: 2004/0167093 (2004-08-01), Lukas
patent: 2004/0176316 (2004-09-01), Renshaw et al.
patent: 2004/0192732 (2004-09-01), Pratt et al.
patent: 2004/0266659 (2004-12-01), LaBerge
patent: 2005/0113449 (2005-05-01), Renshaw
patent: 2005/0129710 (2005-06-01), Renshaw et al.
patent: 2006/0217344 (2006-09-01), Lukas
patent: 2008/0132472 (2008-06-01), Renshaw
patent: 2009/0054370 (2009-02-01), Renshaw
patent: 2009/0215714 (2009-08-01), Renshaw et al.
patent: 3400276 (1985-07-01), None
patent: 0 188 647 (1986-07-01), None
patent: 0 218 190 (1987-04-01), None
patent: 0 431 758 (1991-06-01), None
patent: 0 615 750 (1994-09-01), None
patent: 63-208524 (1988-08-01), None
patent: 08-183737 (1996-07-01), None
patent: 2003332 (1993-11-01), None
patent: WO 93/14076 (1993-07-01), None
patent: WO 99/26620 (1999-06-01), None
patent: WO 00/06174 (2000-02-01), None
patent: WO 00/11952 (2000-03-01), None
patent: WO 01/44265 (2001-06-01), None
patent: WO 01/72288 (2001-10-01), None
Carlezon et al., “Antidepressant-like Effects of Uridine and Omega-3 Fatty Acids Are Potentiated by Combined Treatment in Rats,”Biol Psychiatry, 2005, 57:343-350.
G.-Coviella et al., “Enhancement by Cytidine of Membrane Phospholipid Synthesis,”Journal of Neurochemistry, 1992, 59:338-343.
Hansen, “Blood Nucleoside and Nucleotide Studies in Mental Disease,”The British Journal of Psychiatry, 1972, 121:341-350.
Karkishchenko et al., “Biosynthesis of Endogenous Pyrimidines in Anxiety and Depressive States of Various Etiologies,”S.S. Korsakov Journal of Neuropathology and Psychiatry, 1991, 91:73-74.
Repligen Press Release, “Repligen Reports Phase 1 Results of RG2133 in Bipolar Disorder and Depression Additional Studies Planned with Uridine in Biopolar Disorder,” Jun. 9, 2004.
Repligen Press Release, “Repligen Reports Phase 1 Results of RG2133 in Bipolar Disorder and Depression Additional Studies Planned with Uridine in Biopolar Disorder,” Jun. 10, 2004.
Repligen Press Release, “Repligen's RG2417 Demonstrates Positive Activity in Preclinical Model of Anxiety Data Presented at the Annual Meeting of the Society for Neuroscience,” Oct. 25, 2004.
Repligen Press Release, “Repligen Reports Initial Clinical Data for Secretin in Schizophrenia,” Feb. 4, 2005.
Stradomskii et al., “Pyrimidine Metabolism in Depression Anxiety Disorders,”Izvestiya Severo-Kavkazskogo Mauchnogo Tsentra Vysshei Shkoly Estestvennye Nauki, 1990, 1:106-110.
van Groeningen et al., “Clinical and Pharmacologic Study of Orally Administered Uridine,”Journal of the National Cancer Institute, 1991, 83:437-441.
van Groeningen et al., “Clinical and Pharmacokinetic Studies of Prolonged Administration of High-Dose Uridine Intended for Rescue from 5-FU Toxicity,”Cancer Treatment Reports, 1986, 70:745-750.
Wurtman et al., “Effect of Oral CDP-Choline on Plasma Choline and Uridine Levels in Humans,”Biochemical Pharmacology, 2000, 60:989-992.
Andreazza et al., “Oxidative Stress Markers in Bipolar Disorder: A Meta-Analysis,”J. Affect. Disord. 111:135-144, 2008.
Agnoli et al., “Efficacy of CDPcholine in Chronic Cerebral Vascular Diseases (CCVD),”Proceedings of the International Meeting on Novel Biochemical, Pharmacological and Clinical Aspects of Cytidinediphosphocholine, Sorrento, Italy, Jun. 12-14, 1984, pp. 305-315.
Agut et al., “Cytidine(5')Diphosphocholine Enhances the Ability of Haloperidol to Increase Dopamine Metabolites in the Striatum of the Rat and to Diminish Stereotyped Behavior Induced by Apomorphine,”Neuropharmacology23:1403-1406, 1984.
Alvarez et al., “Double-Blind Placebo-Controlled Study with Citicoline in APOE Genotyped Alzheimer's Disease Patients. Effects on Cognitive Performance, Brain Bioelectrical Activity and Cerebral Perfusion,”Methods Find. Exp. Clin. Pharmacol. 21:633-644, 1999. (Abstract).
Babb et al., “Differential Effect of CDP-Choline on Brain Cytosolic Choline Levels in Younger and Older Subjects as Measured by Proton Magnetic Resonance Spectroscopy,”Psychopharmacology127:88-94, 1996.
Biederman et al., “Non-Stimulant Treatments for ADHD,”Eur. Child Adolesc. Psychiatry9:151-159, 2000.
Boudouresques et al., “Therapeutic Conduct in Light of a Cerebral Vascular Accident and the Use of CDP-Choline,”International Symposium: Brain Suffering and Precursors of Phospholipids, pp. 1-13, 1980.
Bronk et al., “The Transport and Metabolism of Naturally Occurring Pyrimidine Nucleosides by Isolated Rat Jejunum,”J. Physiol. 395:349-361, 1988.
Brown et al., “CNS Complications of Cocaine Abuse: Prevalence, Pathophysiology, and Neuroradiology,”Am. J. Roentgenol. 159:137-147, 1992.
Budney et al., “Marijuana Abstinence Effects in Marijuana Smokers Maintained in Their Home Environment,”Arch. Gen. Psychiatry58:917-924, 2001.
Carlezon et al., “Antidepressant-Like Effects of Cytidine in the Forced Swim Test in Rats,”Biol. Psychiatry51:882-889, 2002.
Castañé et al., “Lack of CB1 Cannabinoid Receptors Modifies Nicotine Behavioural Responses, But Not Nicotine Abstinence,”Neuropharmacology43:857-867, 2002.
Centrone et al., “Use of Citicoline in High Dosages in Acute Cerebrovascular Disease,”Minerva Med. 77:371-373, 1986. English translation of Abstract.
Chang et al., “Neurochemical Alterations in Asymptomatic Abstinent Cocaine Users: A Proton Magnetic Resonance Spectroscopy Study,”Biol. Psychiatry42:1105-1114, 1997.
Christensen et al., “Abnormal Cerebral Metabolism in Polydrug Abusers During Early Withdrawal: A31P MR Spectroscopy Study,”Magn. Reson. Med. 35:658-663, 1996.
Cohen et al., “Decreased Brain Choline Uptake in Older Adults. An In Vivo Proton Magnetic Resonance Spectroscopy Study,”JAMA274:902-907, 1995.
Cohrs et
Clark & Elbing LLP
Lewis Patrick T
The McLean Hospital Corporation
LandOfFree
Pyrimidines, such as uridine, in treatments for patients... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidines, such as uridine, in treatments for patients..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidines, such as uridine, in treatments for patients... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4242674